Ultomiris (ravulizumab-cwvz) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults and children 1 month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
Ultomiris is a type of medicine called a complement inhibitor. It works by blocking a protein called C5, which is part of the immune system. By blocking C5, Ultomiris prevents the formation of a group of proteins called the membrane attack complex.
This helps stop red blood cells from being destroyed inside blood vessels in people with PNH. Doctors prescribe Ultomiris when an adult or child 1 month of age or older needs treatment for PNH.
Ultomiris is given through a vein as an intravenous (IV) infusion by a healthcare provider.
Treatment starts with a weight-based loading dose, followed by the first maintenance infusion two weeks later. After that, Ultomiris is usually given every four or eight weeks, depending on body weight.
The recommended loading dose is based on body weight:
The recommended maintenance dose is also based on body weight:
This information is based on prescribing information, but your healthcare provider may tailor your treatment plan. Always follow their guidance.
In clinical studies of Ultomiris for PNH in adults, the most common side effects occurred in about 32 percent to 39 percent of people. They include:
Ultomiris can cause serious side effects that may require immediate medical attention. These include:
Get medical help right away if you think you are having a serious reaction.
This drug has a boxed warning, the FDA's strongest safety warning, for some of the serious risks mentioned above. A boxed warning does not mean the drug is unsafe for everyone or that everyone faces the same level of risk.
If you experience serious side effects, you can report them to the FDA online or by calling 1-800-FDA-1088. You can also contact the drug's manufacturer.
Alexion Pharmaceuticals, the manufacturer of Ultomiris, offers the Alexion OneSource CoPay Program. Eligible people with commercial insurance may pay as little as $0.
To learn more, visit the Ultomiris financial support page or call 888-765-4747.
You should be vaccinated against meningococcal infection (serogroups A, C, W, Y, and B) according to current Advisory Committee on Immunization Practices (ACIP) recommendations at least two weeks before starting Ultomiris, unless your doctor decides the risks of delaying treatment outweigh the risk of infection. If Ultomiris must be started right away and you are not up to date on these vaccines, you should receive antibacterial drug prophylaxis and get vaccinated as soon as possible.
Tell your doctor if you have any allergies to ravulizumab-cwvz or any ingredients in Ultomiris.
Tell your doctor about all medicines you take, including prescription drugs, over-the-counter medicines, and supplements. Also let your doctor know if you have any other systemic infection or fever.
Do not take Ultomiris if you have an unresolved serious Neisseria meningitidis (meningococcal) infection.
Ultomiris is also FDA-approved to treat adults and children 1 month of age and older with atypical hemolytic uremic syndrome (aHUS).
If you are pregnant, planning to become pregnant, or breastfeeding while taking Ultomiris, talk with your doctor about the risks and benefits. You should not breastfeed during treatment and for eight months after your final dose of Ultomiris.
There is a registry for pregnant women who take Ultomiris. If you are pregnant or become pregnant during treatment, ask your healthcare provider about enrolling, call 833-793-0563, or visit the Ultomiris Pregnancy Registry website.
These answers are fact-checked by our editorial staff.
How effective is Ultomiris?
In clinical studies involving adults with PNH, Ultomiris was compared with another medicine called eculizumab over 26 weeks. Researchers measured how well Ultomiris reduced the need for blood transfusions and controlled hemolysis, which is the breakdown of red blood cells.
In people who had not received a complement inhibitor before, Ultomiris fully blocked the C5 protein by the end of the first infusion. Levels of lactate dehydrogenase (LDH), a blood marker of red blood cell breakdown, returned to the normal range by week 4.
Ultomiris was also shown to maintain control of hemolysis in adults whose PNH was already stable while taking eculizumab. In both studies, Ultomiris was found to be at least as effective as eculizumab based on the studies’ main measures.
How long does Ultomiris take to work for PNH?
In clinical studies, Ultomiris fully blocked a protein called C5 by the end of the first infusion in adults and children with PNH. In people who had not received this type of treatment before, levels of LDH returned to the normal range by week 4.
What tests or monitoring are needed with Ultomiris for PNH?
People starting Ultomiris need meningococcal vaccination at least two weeks before the first dose, unless treatment must start sooner. During each infusion and for at least one hour after it ends, monitoring is recommended for infusion-related reactions. If Ultomiris is stopped, close monitoring for at least 16 weeks is recommended for signs of hemolysis, including elevated LDH, a sudden drop in hemoglobin, or the return of symptoms such as fatigue, dark urine, abdominal pain, or shortness of breath.
What should I do if I miss a dose of Ultomiris for PNH?
If you miss a scheduled Ultomiris infusion, contact your healthcare provider right away. Your infusion date may sometimes be moved by up to seven days before or after the scheduled date. This does not apply to your first maintenance dose.
After that, your next infusions should follow your original treatment schedule.
On myPNHteam, people share their experiences with paroxysmal nocturnal hemoglobinuria, get advice, and find support from others who understand.
Learn more about Ultomiris and paroxysmal nocturnal hemoglobinuria care:
More resources from myPNHteam that mention Ultomiris
Become a member to get even more